A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: Interim Clinical Trial Results

Matthew A Petoe, Samuel A Titchener, Maria Kolic, William G Kentler, Carla J Abbott, David A X Nayagam, Elizabeth K Baglin, Jessica Kvansakul, Nick Barnes, Janine G Walker, Stephanie B Epp, Kiera A Young, Lauren N Ayton, Chi D Luu, Penelope J Allen, Bionics Institute and Centre for Eye Research Australia Retinal Prosthesis Consortium, Peter J Blamey, Robert J Briggs, Owen Burns, Dean Johnson, Lewis Karapanos, Hugh J McDermott, Myra B McGuinness, Rodney E Millard, Peter M Seligman, Robert K Shepherd, Mohit N Shivdasani, Nicholas C Sinclair, Patrick C Thien, Joel Villalobos, Chris E Williams, Jonathan Yeoh, Matthew A Petoe, Samuel A Titchener, Maria Kolic, William G Kentler, Carla J Abbott, David A X Nayagam, Elizabeth K Baglin, Jessica Kvansakul, Nick Barnes, Janine G Walker, Stephanie B Epp, Kiera A Young, Lauren N Ayton, Chi D Luu, Penelope J Allen, Bionics Institute and Centre for Eye Research Australia Retinal Prosthesis Consortium, Peter J Blamey, Robert J Briggs, Owen Burns, Dean Johnson, Lewis Karapanos, Hugh J McDermott, Myra B McGuinness, Rodney E Millard, Peter M Seligman, Robert K Shepherd, Mohit N Shivdasani, Nicholas C Sinclair, Patrick C Thien, Joel Villalobos, Chris E Williams, Jonathan Yeoh

Abstract

Purpose: To report the initial safety and efficacy results of a second-generation (44-channel) suprachoroidal retinal prosthesis at 56 weeks after device activation.

Methods: Four subjects, with advanced retinitis pigmentosa and bare-light perception only, enrolled in a phase II trial (NCT03406416). A 44-channel electrode array was implanted in a suprachoroidal pocket. Device stability, efficacy, and adverse events were investigated at 12-week intervals.

Results: All four subjects were implanted successfully and there were no device-related serious adverse events. Color fundus photography indicated a mild postoperative subretinal hemorrhage in two recipients, which cleared spontaneously within 2 weeks. Optical coherence tomography confirmed device stability and position under the macula. Screen-based localization accuracy was significantly better for all subjects with device on versus device off. Two subjects were significantly better with the device on in a motion discrimination task at 7, 15, and 30°/s and in a spatial discrimination task at 0.033 cycles per degree. All subjects were more accurate with the device on than device off at walking toward a target on a modified door task, localizing and touching tabletop objects, and detecting obstacles in an obstacle avoidance task. A positive effect of the implant on subjects' daily lives was confirmed by an orientation and mobility assessor and subject self-report.

Conclusions: These interim study data demonstrate that the suprachoroidal prosthesis is safe and provides significant improvements in functional vision, activities of daily living, and observer-rated quality of life.

Translational relevance: A suprachoroidal prosthesis can provide clinically useful artificial vision while maintaining a safe surgical profile.

Conflict of interest statement

Disclosure: M.A. Petoe, BI (P), BVT (F,R); S.A. Titchener, BVT (F); M. Kolic, BVT (F,R); W.G. Kentler, BVT (F); C.J. Abbott, BVT (F,R); D.A.X. Nayagam, BI (P), BVT (F); E.K. Baglin, BVT (F,R); J. Kvansakul, BVT (F); N. Barnes, ANU (P), BVT (F); J.G. Walker, BVT (F); S.B. Epp, BVT (F); K.A. Young, BVT (F); L.N. Ayton, none; C.D. Luu, BVT (F); P.J. Allen, BVT (F), CERA (P)

Figures

Figure 1.
Figure 1.
(A) The implanted ocular electrode array (left eye variant) shown with two implantable stimulators (image courtesy of D.A.X. Nayagam). (B) External components including a spectacle-mounted CMOS video camera, head-worn magnetically coupled transmission coils, and a body-worn portable video processor (image courtesy of W.G. Kentler).
Figure 2.
Figure 2.
Indicative ocular aspects of the surgical procedure: (A) The electrode array is inserted into the dissected suprachoroidal pocket. (B) The Dacron patch is sutured to the eye globe and the lead grommet is placed within the orbitotomy. (C) The lateral rectus muscle is replaced and the periosteum is closed over the lead.
Figure 3.
Figure 3.
Study flowchart. All time points are relative to device switch-on and basic fitting in week 1. Weeks 2 to 16 included training on camera use, head scanning, mobility, and task familiarization. Functional assessments comparing device on versus device off occurred in week 17, with repeated assessments at week 20, 32, 44, and 56.
Figure 4.
Figure 4.
(A) Screen-based tasks were performed on a 40-inch touchscreen at arm's length. Shown here is the square localization task. (B) Measuring fingertip distance to target in the modified door task. (C) Tabletop search task. (D) Obstacle avoidance task. The subjects are shown in (B) and (D) wearing a backpack containing wireless equipment for remote control of device parameters.
Figure 5.
Figure 5.
Configuration of the modified door task. All measurements are in centimeters. A black high-contrast target, representing a darkened window or doorway, was randomly positioned at location A, B, or C. The target measured 54 × 70 cm (W × H) and the top-edge was approximately 2 meters above the floor. Subjects started each trial at a random selection of starting points 1, 2, or 3.
Figure 6.
Figure 6.
(A) The six obstacles used to seed the obstacle course: (1) tall pole (17 × 230 × 17 cm); (2) small box – hanging (15 × 30 × 10 cm); (3) large box – hanging (33 × 30 × 10 cm); (4) short pole (34 × 107 × 34 cm); (5) large wastepaper basket (34 × 78 × 34 cm); (6) small wastepaper basket (28 × 34 × 28 cm). (B) An example configuration of the obstacle course. A random selection of five of the six obstacles were placed at 2.55-metre intervals along a 1.75 × 20.00 m corridor.
Figure 7.
Figure 7.
(A) Fundus images of the electrode array at 12 weeks after surgery for a right eye implantation (S4), visualized using a CLARUS 500 in wide-field configuration (133° retinal field) with RGB illumination (left image) and infrared illumination (right image). A blue cross marks the fovea. The leading edge of the electrode array is surgically inserted toward the optic disc, with the trailing edge and lead wire (not shown) extending toward the periphery. (B) OCT image of the electrode array at 4 weeks after surgery (S2). (Left) The infrared image was used to orientate the B-scan position (green line) through the retina and electrode array. (Right) The retina and electrodes could be visualized on OCT B-scan. (C) Magnified view of the region in the orange box in (B), showing the inner retina, RPE, choroid, and suprachoroidal electrode. The yellow arrow demonstrates an example measurement of electrode-to-retina distance (200 µm), defined as the distance from electrode to the outer retina boundary.
Figure 8.
Figure 8.
(A) Electrode to retina distances obtained from OCT images. Each different color (black, magenta, blue, red) indicates data for each subject. Individual electrode measurements are shown as dots. A solid line connects the median values between time points. A vertical line at −8 weeks indicates the date of surgery. A vertical line at 0 weeks indicates the date of device activation (‘switch-on’). (B) Device thresholds for a subset of five phosphenes per subject were assessed throughout the 56-week period. Phosphenes are typically in a single electrode configuration (open squares) for electrodes nearest the fovea and paired electrode configuration (solid dots) for electrodes at the periphery where higher charge requirements have been observed. Defined safe charge limits of 250 nC (single electrode) and 500 nC (paired electrode) are indicated with dotted horizontal lines. A solid line describes a linear regression for each subject. (C) Device thresholds for the same subset of five phosphenes per subject versus eccentricity from the fovea (degrees). A SOLID LINE describes a linear regression for each subject. (D) Device thresholds for the same subset of five phosphenes per subject versus electrode-to-retina distance (in micrometers). A solid line describes a linear regression for each subject.
Figure 9.
Figure 9.
Results for the square localization task comparing device on (blue) versus device off (red) versus a scrambled condition (magenta). (A) Average pointing error (in degrees) from touch location to the target center for 24 trials of each condition. The boundary of the 10° wide square target is indicated by a dotted horizontal line. (B) Average response time (seconds) for 24 trials of each condition. Circles show the average of 24 trials at each time point, shaded progressively darker for later dates and labelled with week number. The height of the bar is each subject's average across all time points. Statistical significance of within-subject comparisons is shown; *** P < 0.001; ** P < 0.01.
Figure 10.
Figure 10.
Results for the motion discrimination task comparing device on (blue) versus device off (red) versus a scrambled condition (magenta). (A) Success rate at 7°/s. (B) Success rate at 15°/s. (C) Success rate at 30°/s. Chance level (25%) is shown as a dotted horizontal line. Circles show the average of 24 trials at each time point, shaded progressively darker for later dates and labelled with week number. The height of the bar is each subject's average across all time points. Statistical significance of within-subject comparisons is shown; *** P < 0.001; ** P < 0.01; NS = not significant. Friedman tests for S3 at 7°/s were significant, but post hoc comparisons were not; hence, significance is not indicated for these data.
Figure 11.
Figure 11.
Results for the spatial discrimination task comparing device on (blue) versus device off (red) for subjects S1 to S3. (A) Percentage correct of 24 trials. The passing criterion (75%) is shown as a dotted horizontal line. (B) Mean response time (seconds). Circles show the average of 24 trials at each time point, shaded progressively darker for later dates and labelled with week number. The height of the bar is each subject's average across all time points. Significance was not tested. Subject S4 did not attempt this task.
Figure 12.
Figure 12.
Results for the modified door task comparing device on (blue) versus device off (red). (A) Rate of successful touches of target (%). (B) Touch distance from fingertip to target including successful touches. (C) Time taken to reach target. Circles show the average of 10 trials at each time point, shaded progressively darker for later dates and labelled with week number. The height of the bar is each subject's average across all time points. Statistical significance of within-subject comparisons is shown; *** P < 0.001; * P < 0.05; NS = not significant.
Figure 13.
Figure 13.
Results for the tabletop search task comparing device on (blue) versus device off (red). (A) Success rate (%) for verbally indicating object location on a 3 × 3 grid. (B) Success rate (%) for identifying object type (1 of 6). (C) Success rate (%) for contacting the object. (D) Distance from fingertip to object including successful touches. Chance level is indicated as a horizontal dotted line in (A) and (B). Circles show the average of 20 trials at each time point, shaded progressively darker for later dates and labelled with week number. The height of the bar is each subject's average across all time points. Statistical significance of within-subject comparisons is shown; *** P < 0.001; ** P < 0.01; * P < 0.05; NS = not significant.
Figure 14.
Figure 14.
Response matrices for tabletop object identification pooled from all time points. (A) Comparisons with device on for reported object versus actual object demonstrate low scores for object identification but also clustering of responses according to the size of the actual object. (B) Comparisons with device off for reported object versus actual object. Cell text indicates incidence percent and fraction of actual object incidence. Row numerator totals (n) are the response incidence. Column numerator totals (N) are the total object incidence. (C) Photos of the objects used for tabletop search (from left): placemat, plate, bowl, cup, can, and fork.
Figure 15.
Figure 15.
Results for the obstacle avoidance task comparing device on (blue) versus device off (red). (A) Success rate (%) for verbally indicating object location on approach. (B) Walking speed for each trial, expressed as percent of preferred walking speed (PWS). (C) Collision rate (%) for each trial. (D) Percent of trials with zero collisions or contact. Circles show the average of 10 trials at each time point, shaded progressively darker for later dates and labelled with week number. The height of the bar is each subject's average across all time points. Statistical significance of within-subject comparisons is shown; *** P < 0.001; ** P < 0.01; NS = not significant.
Figure 16.
Figure 16.
Group means and subject means for FLORA in four task categories: (A) orientation, (B) mobility, (C) activities of daily living, and (D) interacting with others. (EH) The relative contribution of vision (with respect to other senses) was determined for these same tasks. One subject is excluded from this analysis (see text). Group averages are shown as blue lines (device on) and red lines (device off). Subject averages are shown as circles (device on) and squares (device off). The color key for individual subject data is described in the legend of (A) and (E).
Figure 17.
Figure 17.
Subjects reported on the Impact of Vision Impairment (IVI-VLV) on their (A) emotional well-being and (B) activities of daily living, mobility, and safety in the month before each assessment. Subject averages are shown as solid lines. Assessments for subject S4 were markedly influenced by external stressors that were unrelated to the device or the study.

References

    1. Dias MF, Joo K, Kemp JA, et al. .. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res. 2018; 63: 107–131.
    1. Russell S, Bennett J, Wellman JA, et al. .. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017; 390: 849–860.
    1. Ayton LN, Barnes N, Dagnelie G, et al. .. An update on retinal prostheses. Clin Neurophysiol. 2020; 131: 1383–1398.
    1. Luo YH-L, da Cruz L.. The Argus II retinal prosthesis system. Prog Retin Eye Res. 2016; 50: 89–107.
    1. Palanker D, Le Mer Y, Mohand-Said S, Muqit M, Sahel JA. Photovoltaic restoration of central vision in atrophic age-related macular degeneration. Ophthalmology. 2020; 127: 1097–1104.
    1. Edwards TL, Cottriall CL, Xue K, et al. .. Assessment of the electronic retinal implant Alpha AMS in restoring vision to blind patients with end-stage retinitis pigmentosa. Ophthalmology. 2018; 125: 432–443.
    1. Stingl K, Bartz-Schmidt KU, Besch D, et al. .. Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc R Soc B Biol Sci. 2013; 280: 20130077.
    1. Ayton LN, Blamey PJ, Guymer RH, et al. .. First-in-human trial of a novel suprachoroidal retinal prosthesis. PLoS One. 2014; 9: e115239.
    1. Villalobos J, Nayagam DAX, Allen PJ, et al. .. A wide-field suprachoroidal retinal prosthesis is stable and well tolerated following chronic implantation. Invest Ophth Vis Sci. 2013; 54: 3751–3762.
    1. Fujikado T, Kamei M, Sakaguchi H, et al. .. One-year outcome of 49-channel suprachoroidal–transretinal stimulation prosthesis in patients with advanced retinitis pigmentosa. Invest Ophth Vis Sci. 2016; 57: 6147–6157.
    1. Ayton LN, Apollo NV, Varsamidis M, Dimitrov PN, Guymer RH, Luu CD.. Assessing residual visual function in severe vision loss. Invest Ophth Vis Sci. 2014; 55: 1332–1338.
    1. Klein M, Birch D.. Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Doc Ophthalmol. 2009; 119: 217–224.
    1. Dacey DM, Petersen MR.. Dendritic field size and morphology of midget and parasol ganglion cells of the human retina. P Natl Acad Sci USA. 1992; 89: 9666–9670.
    1. Barnes N, Scott AF, Lieby P, et al. .. Vision function testing for a suprachoroidal retinal prosthesis: effects of image filtering. J Neural Eng. 2016; 13: 15.
    1. Saunders AL, Williams CE, Heriot W, et al. .. Development of a surgical procedure for implantation of a prototype suprachoroidal retinal prosthesis. Clin Exp Ophthalmol. 2014; 42: 665–674.
    1. Shivdasani MN, Sinclair NC, Dimitrov PN, et al. .. Factors affecting perceptual thresholds in a suprachoroidal retinal prosthesis. Invest Ophthalmol Vis Sci. 2014; 55: 6467–6481.
    1. Ayton LN, Rizzo JF III, Bailey IL, et al. .. Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the International HOVER Taskforce. Transl Vis Sci Technol. 2020; 9: 25.
    1. Ahuja AK, Behrend MR.. The Argus II retinal prosthesis: factors affecting patient selection for implantation. Prog Retin Eye Res. 2013; 36: 1–23.
    1. Petoe MA, McCarthy CD, Shivdasani MN, et al. .. Determining the contribution of retinotopic discrimination to localization performance with a suprachoroidal retinal prosthesis. Invest Ophth Vis Sci. 2017; 58: 3231–3239.
    1. Bach M, Wilke M, Wilhelm B, Zrenner E, Wilke R.. Basic quantitative assessment of visual performance in patients with very low vision. Invest Ophth Vis Sci. 2010; 51: 1255–1260.
    1. Humayun MS, Dorn JD, da Cruz L, et al. .. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012; 119: 779–788.
    1. Finger RP, McSweeney SC, Deverell L, et al. .. Developing an instrumental activities of daily living tool as part of the low vision assessment of daily activities protocol. Invest Ophth Vis Sci. 2014; 55: 8458–8466.
    1. Geruschat DR, Flax M, Tanna N, et al. .. FLORA: phase I development of a functional vision assessment for prosthetic vision users. Clin Exp Optom. 2015; 98: 342–347.
    1. Finger RP, Tellis B, Crewe J, Keeffe JE, Ayton LN, Guymer RH.. Developing the Impact of Vision Impairment-Very Low Vision (IVI-VLV) Questionnaire as part of the LoVADA protocol. Invest Ophth Vis Sci. 2014; 55: 6150–6158.
    1. Kroenke K, Spitzer RL, Williams JB.. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16: 606–613.
    1. Wittkowski KM.Friedman-type statistics and consistent multiple comparisons for unbalanced designs with missing data. J Am Stat Assoc. 1988; 83: 1163–1170.
    1. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available at: .
    1. Wittkowski KM, Song T.. muStat: Prentice rank sum test and McNemar test. R package version 1.7.0. Vienna, Austria: R Foundation for Statistical Computing; 2012. Available at: .
    1. Conover WJ.Practical nonparametric statistics. New York: John Wiley & Sons; 1998.
    1. Holm S.A simple sequentially rejective multiple test procedure. Scand J Stat. 1979; 6: 65–70.
    1. Ghodasra DH, Chen A, Arevalo JF, et al. .. Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol. 2016; 16: 52.
    1. Muqit MMK, Hubschman JP, Picaud S, et al. .. PRIMA subretinal wireless photovoltaic microchip implantation in non-human primate and feline models. PloS One. 2020; 15: e0230713.
    1. Schaffrath K, Schellhase H, Walter P, et al. .. One-year safety and performance assessment of the Argus II retinal prosthesis: a postapproval study. Jama Ophthalmol. 2019; 137: 896–902.
    1. Luo YH-L, Zhong JJ, da Cruz L.. The use of Argus II retinal prosthesis by blind subjects to achieve localisation and prehension of objects in 3-dimensional space. Graefes Arch Clin Exp Ophthalmol. 2014; 253: 1907–1914.
    1. Curcio CA, Allen KA.. Topography of ganglion cells in human retina. J Comp Neurol. 1990; 300: 5–25.
    1. Yue L, Weiland JD, Roska B, Humayun MS.. Retinal stimulation strategies to restore vision: fundamentals and systems. Prog Retin Eye Res. 2016; 53: 21–47.
    1. Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Marmor M, Marc RE.. Retinal remodeling in human retinitis pigmentosa. Exp Eye Res. 2016; 150: 149–165.
    1. Ahuja AK, Dorn JD, Caspi A, et al. .. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011; 95: 539–543.
    1. Dorn JD, Ahuja AK, Caspi A, et al. .. The Detection of motion by blind subjects with the epiretinal 60-electrode (Argus II) retinal prosthesis. JAMA Ophthalmol. 2013; 131: 183–189.
    1. Titchener SA, Kvansakul J, Shivdasani MN, et al. .. Oculomotor responses to dynamic stimuli in a 44-channel suprachoroidal retinal prosthesis. Transl Vis Sci Technol. 2020; 9: 31–31.
    1. Stingl K, Bartz-Schmidt KU, Besch D, et al. .. Subretinal visual implant Alpha IMS – clinical trial interim report. Vision Res. 2015; 111: 149–160.
    1. Stingl K, Schippert R, Bartz-Schmidt KU, et al. .. Interim results of a multicenter trial with the new electronic subretinal implant Alpha AMS in 15 patients blind from inherited retinal degenerations. Front Neurosci. 2017; 11: 445.
    1. Kartha A, Sadeghi R, Barry MP, et al. .. Prosthetic visual performance using a disparity-based distance-filtering system. Transl Vis Sci Technol. 2020; 9: 27–27.
    1. Endo T, Kanda H, Hirota M, Morimoto T, Nishida K, Fujikado T.. False reaching movements in localization test and effect of auditory feedback in simulated ultra-low vision subjects and patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2016; 254: 947–956.
    1. Stingl K, Bach M, Bartz-Schmidt KU, et al. .. Safety and efficacy of subretinal visual implants in humans: methodological aspects. Clin Exp Optom. 2013; 96: 4–13.
    1. Wilke R, Bach M, Wilhelm B, Durst W, Trauzettel-Klosinski S, Zrenner E.. Testing visual functions in patients with visual prostheses. Artificial Sight. New York: Springer; 2007;91–110.
    1. da Cruz L, Dorn JD, Humayun MS, et al. .. Five-year safety and performance results from the Argus II Retinal prosthesis system clinical trial. Ophthalmology. 2016; 123: 2248–2254.
    1. Finger RP, Ayton LN, Deverell L, et al. .. Developing a very low vision orientation and mobility test battery (O&M-VLV). Optom Vis Sci. 2016; 93: 1127–1136.
    1. Barry MP, Dagnelie G.. Hand-camera coordination varies over time in users of the Argus II retinal prosthesis system. Front Syst Neurosci. 2016; 10: 41.
    1. Sabbah N, Authie CN, Sanda N, Mohand-Said S, Sahel JA, Safran AB.. Importance of eye position on spatial localization in blind subjects wearing an Argus II retinal prosthesis. Invest Ophth Vis Sci. 2014; 55: 8259–8266.
    1. Turano KA, Geruschat DR, Baker FH, Stahl JW, Shapiro MD.. Direction of gaze while walking a simple route: persons with normal vision and persons with retinitis pigmentosa. Optom Vis Sci. 2001; 78: 667–675.
    1. McCarthy C, Walker JG, Lieby P, Scott A, Barnes N.. Mobility and low contrast trip hazard avoidance using augmented depth. J Neural Eng. 2014; 12: 016003.
    1. Garcia S, Petrini K, Rubin GS, Da Cruz L, Nardini M. Visual and non-visual navigation in blind patients with a retinal prosthesis. PloS One. 2015; 10: e0134369.
    1. Caspi A, Roy A, Wuyyuru V, et al. .. Eye movement control in the Argus II retinal-prosthesis enables reduced head movement and better localization precision. Invest Ophthalmol Vis Sci. 2018; 59: 792–802.
    1. Titchener SA, Shivdasani MN, Fallon JB, Petoe MA.. Gaze compensation as a technique for improving hand-eye coordination in prosthetic vision. Transl Vis Sci Technol. 2018; 7: 2.
    1. Geruschat DR, Richards TP, Arditi A, et al. .. An analysis of observer-rated functional vision in patients implanted with the Argus II retinal prosthesis system at three years. Clin Exp Optom. 2016; 99: 227–232.
    1. Delyfer MN, Gaucher D, Mohand-Saïd S, et al. .. Improved performance and safety from Argus II retinal prosthesis post-approval study in France. Acta Ophthalmol. 2020, doi:10.1111/aos.14728. Online ahead of print.
    1. Dagnelie G, Christopher P, Arditi A, et al. .. Performance of real-world functional vision tasks by blind subjects improves after implantation with the Argus II retinal prosthesis system. Clin Exp Ophthalmol. 2017; 45: 152–159.
    1. Misajon R, Hawthorne G, Richardson J, et al. .. Vision and quality of life: the development of a utility measure. Invest Ophthalmol Vis Sci. 2005; 46: 4007–4015.
    1. Duncan JL, Richards TP, Arditi A, et al. .. Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis. Clin Exp Optom. 2017; 100: 144–150.

Source: PubMed

3
Tilaa